LUCD Lucid Diagnostics Inc

$LUCD , October 01, 2026 Recommendations Needham sees no reason for Lucid Diagnostics selloff today LUCD | 12:16 PM Needham says the firm spoke to Lucid Diagnostics to understand possible reasons for today's selloff. Management is not aware of news or other factors that would justify the pullback, and highlighted Lucid's recent press release about reimbursement progress, the analyst tells investors in a research note. As such, Needham is a buyer of the stock on today's selloff. It keeps a Buy rating on Lucid Diagnostics with a $3 price target. The stock in midday trading is down 27% to 55c. Related Articles

$LUCD Lucid effectively has national coverage for Medicare patients RIGHT NOW by sending tests to the new CLIA lab in Texas. How is the market not realizing this? Here is another precedent for this pathway - Aspira stated in a recent SEC filing that because their tests are performed in Texas, that "Novitas Solutions essentially provides national coverage for patients enrolled in Medicare." https://www.sec.gov/Archives/edgar/data/926617/000149315225004349/forms-1a.htm? Aspira has an LCD with Novitas, but Novitas is very clear that in the absence of an LCD or NCD, they cover based on reasonable and necessary guidelines. We have strong evidence for reasonable and necessary which continues to be validated by professional societies and LBMs like Concert. For a long time, Lucid was throttling test volume growth due to lack of coverage. Now Lucid sales reps can go wild selling to the Medicare population. In other words, this is where the rubber meets the road. Test volume and revenue should start to increase in Q4 2026.

$LUCD Y'all are probably sick of the EXAS comparisons, but EXAS traded at $0.44 on Nov 28 2008. They were facing imminent delisting from Nasdaq. A year earlier they had an FDA warning letter sparking questions whether their test was even viable. After that, they slashed 67% of their work force. They were absolutely in survival mode. But look at them now, Abbott paid more than $20B. We have a rock star test in Esoguard. The KOLs see it, the AGA sees it, AFS sees it. These endorsements matter. They guide medical policy. They decide who gets the test and who doesn't. They're the foundation for reimbursement. The foundation is strong and getting stronger (latest AGA draft guideline). Some payers are starting to build on it (VA, Concert). More will come with time. No question not getting the LCD last night was a disappointment, but given the lab in TX, it has no material impact. Revenue should start climbing Q4. I am staying the course!

$LUCD Just a reminder, developing a new screening test takes a LONG TIME. Now you see Cologuard commercials on NFL games. It's a household name. Well, it took over 20 years to get to this point. Esoguard is barely getting started. Relax people.

$LUCD under the new suggested and in my opinion very soon to be accepted AGA guidance...a Kunzmann score of 6.0 now gives us a total accessible market of $102 Billion... do you understand why they are shaking the tree yet???

$LUCD I don’t know what will Happen to lucd, but you probably don’t need to worry about a R/S any time soon. Lucd would get the 6 month grace period just like PAVM did. If Moldx takes 6 more months to get their shit together then we probably have bigger problems than a R/S

$LUCD ladies and gentlemen without saying it as absolute only to avoid bad luck....let's just look at it this way. Imagine being accepted in texas but not elsewhere....do you really this moldx and cms would want that look? It wouldnt make any sense at all. 2 arms just moving at a slightly different speed of approval. Do you think Texas although independent most likely knows what CMS is doing? I think that answer is obvious. It's also VERY likely we get updated guidelines from the associations upcoming...we even have the AFA conference this week with some great news to present and perhaps more. We are moving toward the standard of care in a massive market....MASSIVE

$LUCD 1891 watchers on a stock with a TAM of 30-60Billion is insane. Once CMS acceptance occurs and trending begins look out. I added my "final" 10k shares just now to take it to 200k shares cost avg of 1.03. I'm banking on these ridiculously realistic assumptions. - $1900/test allowable reimbursement for an already approved FDA test with ZERO competition in a Total accessable market of 30-60B will bring a market cap well above 195m with is my current cost avg. I almost feel like I'm taking crazy pills every time I say it...

$LUCD guys if this stock God willing works out, can we find the next stick together lol I developed a trauma bond with the members of this board over this stock loool met a lot of smart people here that know there stuff would love to continue this

$LUCD F it. Bought another 2k shares when it dipped to 93 cents. At this point I’m all in. I either win big or not at all.

$LUCD AI believes esoguard could save 2,000–4,000 lives per year, with ~3,000/year being a defensible midpoint. The speed and ineptitude of our government is indirectly killing thousands.

$LUCD a lot of volume just pushed the price up a bit, so someone is buying... At least temporarily.

$LUCD I wouldn't count on seeing big insider buys AND I don't think the street gives a shit either way. I don't care if Lishan add's 50k shares right now. They need to be singularly focused on driving revenue through Highmark, the V.A. and the other new plans through Lyric. The AGA's new draft Clinical Practice Guideline for Screening for Barrett's Esophagus and Esophageal Adenocarcinoma is now in public comment. The public-comment period runs through October 28, 2026. This SHOULD be huge for us. These are the SME guidelines that determine the rate of adoption and commercial viability.

$LUCD can anybody please calm me down and give me encouragement , the imminent talk of aklog is really starting to bother me and I’m starting to feel a little betrayed and wondering if there is a future r/s how much that will effect future profit I could have made

$LUCD Big, big news. "Lucid will begin submitting Medicare claims this month under EsoGuard's PLA code, 0114U, for tests performed at its Texas laboratory." That's an excellent stopgap as we wait for MolDX.

$LUCD Enough is enough. There are a dozen or more long timers here. Let’s each commit to emailing Moldx. I will.

$LUCD Back on 6/4 I put the odds at: 25% June 50% by end of August 70% by end of September. September isn’t over yet. Today’s news doesn’t mean MolDX has made its decision. But Medicare billing is now moving forward through the Texas lab while the MolDX reconsideration continues in California. Sometimes the door opens. Sometimes you find another door. I still like where we’re standing.

$LUCD not a terrible volume move today, but probably just a bunch of traders playing the chance of a decision coming tomorrow.

$LUCD i waited 5yrs for $exas (lot of us did) and it was the same thing there; thats here... until it wasnt - get off the board and being emotional and stop in from time to time or when its xmas

$LUCD the VA alone is 9m covered lives and many of those are in the sweet-spot for this screening...if they can get 2% x $1900+...well...it should be worth more than 50c/share....